Protocol Ledger

NCT07404865 · Phase III · RECRUITING

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Interventional Phase III clinical trial protocol NCT07404865 sponsored by Vor Biopharma in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-26 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07404865
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07404865
Protocol FieldVerified Registry Value
NCT IdentifierNCT07404865
Consolidated Lead SponsorVor Biopharma
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2026-02-26
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI